Lorlatinib, a third-generation ALK TKI, has shown encouraging results regarding anti-tumor effects, overcoming intrinsic resistance observed with ALK kinase domain mutations more effectively than first- and second-generation TKIs (e.g., crizotinib and ceritinib) [[22], [23], [24]]. The gene discussed is ALK; the disease is neoplasm.